Skip to main content

Table 5 Description of adverse events that are likely related to antiretroviral therapy

From: Cost analysis of HIV treatment and drug-related adverse events when fixed-dose combinations of antiretrovirals (FDCs) were stopped, versus continuation with FDCs

Adverse events Severity (grade) Resources consumed for the management of the adverse event
Non-exposed group (n = 150)   
1. Dizziness after an error in taking AtriplaTM 1 -
2. Neuropsychiatric: insomnia, anxiety, and abnormal dreams* 1 -
Exposed group (n = 75)   
1. Neuropsychiatric: dizziness 2 -
2. Neuropsychiatric: insomnia, abnormal dreams* 2 -
3. Neuropsychiatric: depression, insomnia* 1 -
4. Neuropsychiatric: insomnia 2 Infectious disease consult
5. Diarrhoea 2 -
6. Vomiting 2 -
7. Hepatic toxicity 4 Specialist and nursing consults, hospital admissions, chest x-rays, abdominal ultrasound, and hepatic biopsy
8. Neuropsychiatric: dizziness, insomnia, and abnormal dreams* 2 -
9. Neuropsychiatric: insomnia, anxiety, loss of concentration, abnormal dreams, and HIV encephalopathy after stopping treatment* 4 Infectious disease consults, hospital admissions, cranial CAT scan, cerebral MRI, and lumbar puncture
10. Neuropsychiatric: dizziness 1 -
11. Psychiatric: depression, insomnia, anxiety, abnormal dreams, and hallucinations* 3 Emergency department admission, mental health consult
12. Hepatic toxicity 3 Infectious disease consult, nursing, biochemistry, serology, and abdominal ultrasound
13. Neuropsychiatric: dizziness, insomnia, headache, and abnormal dreams* 2 Infectious disease consult
14. Diarrhoea 2 -
  1. *Patients with more than one type of neuropsychiatric adverse event. The grade of the more severe AE is specified.